Pharma villain Martin Shkreli has been fired from his position as CEO of drug company KaloBios, following his arrest last week on security fraud charges and subsequent resignation from Turing Pharmaceuticals.
Shkreli, as part of an investor group, acquired 70 percent of outstanding shares for KaloBios on November 19th. The reviled businessman also served (if briefly) as Chief Executive Officer for the San Francisco-based drug-maker, which specializes in treatments for rare and orphaned diseases, Gizmodo reports.
KaloBios announced the decision on Monday (Dec. 21), also noting the resignation of Tony Chase, who joined the company's board in November.
Last week, Shkreli was arrested for security fraud and resigned from his position as CEO of Turing Pharmaceuticals. At that company, he made headlines (and enemies) by raising the price of antiparasitic Daraprim from $13.50 to $750 per tablet.
Shkreli reached a new level of pop culture infamy after it was revealed he purchased the Wu-Tang Clan's sole copy of LP Once Upon a Time in Shaolin for $2 million. In one of the greatest tweets in Internet history, the FBI clarified that they hadn't seized the relic-like LP after the arrest.